Does OBINUTUZUMAB Cause Diffuse large b-cell lymphoma recurrent? 41 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 41 reports of Diffuse large b-cell lymphoma recurrent have been filed in association with OBINUTUZUMAB (Gazyva). This represents 0.3% of all adverse event reports for OBINUTUZUMAB.
41
Reports of Diffuse large b-cell lymphoma recurrent with OBINUTUZUMAB
0.3%
of all OBINUTUZUMAB reports
2
Deaths
0
Hospitalizations
How Dangerous Is Diffuse large b-cell lymphoma recurrent From OBINUTUZUMAB?
Of the 41 reports, 2 (4.9%) resulted in death.
Is Diffuse large b-cell lymphoma recurrent Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OBINUTUZUMAB. However, 41 reports have been filed with the FAERS database.
What Other Side Effects Does OBINUTUZUMAB Cause?
Off label use (1,584)
Neutropenia (1,276)
Febrile neutropenia (955)
Covid-19 (942)
Pyrexia (920)
Thrombocytopenia (889)
Disease progression (831)
Infusion related reaction (789)
Pneumonia (662)
Anaemia (640)
What Other Drugs Cause Diffuse large b-cell lymphoma recurrent?
RITUXIMAB (1,359)
CYCLOPHOSPHAMIDE (1,007)
VINCRISTINE (957)
DOXORUBICIN (953)
PREDNISONE (738)
CYTARABINE (406)
DEXAMETHASONE (402)
ETOPOSIDE (375)
CISPLATIN (306)
GEMCITABINE (280)
Which OBINUTUZUMAB Alternatives Have Lower Diffuse large b-cell lymphoma recurrent Risk?
OBINUTUZUMAB vs OCELLA
OBINUTUZUMAB vs OCRELIZUMAB
OBINUTUZUMAB vs OCRIPLASMIN
OBINUTUZUMAB vs OCTINOXATE\OCTISALATE\ZINC
OBINUTUZUMAB vs OCTINOXATE\OCTOCRYLENE